Submission Details
| 510(k) Number | K251742 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 06, 2025 |
| Decision Date | February 13, 2026 |
| Days to Decision | 252 days |
| Submission Type | Dual Track |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K251742 is an FDA 510(k) clearance for the VELO Respiratory Test, a Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents (Class II — Special Controls, product code QOF), submitted by Lex Diagnostics Limited (Melbourn, GB). The FDA issued a Cleared decision on February 13, 2026, 252 days after receiving the submission on June 6, 2025. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3981.
| 510(k) Number | K251742 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 06, 2025 |
| Decision Date | February 13, 2026 |
| Days to Decision | 252 days |
| Submission Type | Dual Track |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | QOF — Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.3981 |
| Definition | A Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The Sars-cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-target Test Is An In Vitro Diagnostic Device Intended For The Detection And Identification Of Sars-cov-2 And Other Microbial Agents When In A Multi-target Test In Human Clinical Respiratory Specimens From Patients Suspected Of Respiratory Infection Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. The Device Is Intended To Aid In The Diagnosis Of Respiratory Infection In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data Or Other Risk Factors. |